Annovis Bio Inc. (US03615A1088)
XSTU 
Summary
US03615A1088 Chart
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Annovis Bio Targets March 2027 Alzheimer's Readout, Prepares Rolling NDA
Annovis Bio NYSE: ANVS said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer's disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its efficacy requirements.
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy
Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Annovis Bio Inc. (US03615A1088) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Annovis Bio Inc. ever had a stock split?
Annovis Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Maria L. Maccecchini CEO | XSTU Exchange | US03615A1088 ISIN |
| US Country | 7 Employees | - Last Dividend | - Last Split | 12 Feb 2010 IPO Date |
Overview
Annovis Bio, Inc. is a pioneering clinical stage drug platform company committed to addressing the complexities of neurodegeneration. The company focuses on the development of novel drugs designed to treat a wide range of chronic neurodegenerative diseases. Since its inception in 2008, Annovis Bio has been deeply involved in understanding and innovating therapeutic solutions for some of the most challenging conditions like Alzheimer's disease and Parkinson's disease. Based in Berwyn, Pennsylvania, the company leverages its scientific expertise and extensive research capabilities to develop treatments that aim to halt or potentially reverse the progression of neurodegenerative disorders, improving the quality of life for patients worldwide.
Products and Services
- Buntanetap - Currently in Phase 3 clinical trials, Buntanetap is Annovis Bio’s lead drug candidate, showing promise in the treatment of Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative diseases. This product stands out for its innovative approach aimed at not just alleviating symptoms but also targeting the underlying causes of neurodegeneration.
- ANVS405 - This drug candidate is under development for the protection of the brain following traumatic brain injury (TBI) and/or stroke. ANVS405 represents a significant step forward in post-injury care, focusing on neuroprotection and the prevention of further neuronal degradation after acute events, a critical aspect of recovery and rehabilitation.
- ANVS301 - Currently in Phase I clinical trials, ANVS301 is designed to increase cognitive capability in the later stages of Alzheimer's disease and dementia. The focus of ANVS301 is on enhancing brain function and cognitive performance, offering hope for improved quality of life in conditions often considered inexorably progressive.
